CDP323 Biomarker Study

Phase 1/2 Completed 71 enrolled UCB Pharma Biogen · collab

RandomizedParallel-groupDouble-blindBasic science

Summary

Comparison of the effects of different CDP323 doses given over a period of four weeks on blood biomarkers in subjects with relapsing forms of multiple sclerosis.

Timeline

Start: 2008-07
Primary completion: 2009-03
Completion: 2009-03

Publications

Wolf C, Sidhu J, Otoul C, Morris DL, Cnops J, Taubel J, Bennett B. Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study. PLoS One. 2013;8(3):e58438. doi: 10.1371/journal.pone.0058438. Epub 2013 Mar 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	UCB-1184197	Small molecule	100 mg	Oral
Subject	UCB-1184197	Small molecule	500 mg	Oral
Subject	UCB-1184197	Small molecule	1000 mg	Oral

CDP323 Biomarker Study

Summary

Timeline

Publications

Drugs

Indications